Legal & General Group Plc Takes $395,000 Position in Pulse Biosciences, Inc $PLSE

Legal & General Group Plc purchased a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 14,240 shares of the company’s stock, valued at approximately $395,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Pulse Biosciences in the second quarter valued at approximately $40,672,000. Bank of America Corp DE increased its stake in shares of Pulse Biosciences by 8.2% during the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock worth $18,698,000 after purchasing an additional 65,884 shares during the last quarter. State Street Corp increased its stake in shares of Pulse Biosciences by 6.0% during the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after purchasing an additional 25,187 shares during the last quarter. Brooklyn Investment Group lifted its stake in shares of Pulse Biosciences by 330.7% in the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares during the last quarter. Finally, Portolan Capital Management LLC acquired a new stake in shares of Pulse Biosciences in the 3rd quarter valued at $1,809,000. Institutional investors own 76.95% of the company’s stock.

Insider Buying and Selling

In other news, COO Liane Teplitsky bought 1,036 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, with a total value of $49,966.28. Following the completion of the transaction, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 4,095 shares of company stock valued at $199,931 over the last three months. 74.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on PLSE. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 price objective on Pulse Biosciences in a report on Monday, August 10th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Needham & Company LLC started coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Stock Down 8.4%

Pulse Biosciences stock opened at $48.79 on Wednesday. The business has a 50 day moving average price of $38.88 and a two-hundred day moving average price of $28.41. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -41.35 and a beta of 1.63. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $55.37.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.